Cargando…

Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens

Adoptive T cell-receptor therapy (ACT) could represent a promising approach in the targeted treatment of epithelial ovarian cancer (EOC). However, the identification of suitable tumor-associated antigens (TAAs) as targets is challenging. We identified and prioritized TAAs for ACT and other immunothe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schossig, Paul, Coskun, Ebru, Arsenic, Ruza, Horst, David, Sehouli, Jalid, Bergmann, Eva, Andresen, Nadine, Sigler, Christian, Busse, Antonia, Keller, Ulrich, Ochsenreither, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916968/ https://www.ncbi.nlm.nih.gov/pubmed/36768616 http://dx.doi.org/10.3390/ijms24032292

Ejemplares similares

Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy
por: Arsenic, Ruza, et al.
Publicado: (2015)

Epithelial Ovarian Cancer: Focus on Targeted Therapy
por: Markman, M., et al.
Publicado: (2010)

Fertility-Sparing Surgery in Early Epithelial Ovarian Cancer: A Viable Option?
por: Fotopoulou, Christina, et al.
Publicado: (2012)

Immunohistochemical analysis of PDK1 expression in breast cancer
por: Arsenic, Ruza
Publicado: (2014)

The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases
por: Biskup, Karina, et al.
Publicado: (2014)

Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer
por: Biskup, Karina, et al.
Publicado: (2021)

In Situ N-Glycosylation Signatures of Epithelial Ovarian Cancer Tissue as Defined by MALDI Mass Spectrometry Imaging
por: Grzeski, Marta, et al.
Publicado: (2022)

The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis
por: Ruan, Guanyu, et al.
Publicado: (2018)

Predictive and Prognostic Value of sPRR in Patients with Primary Epithelial Ovarian Cancer
por: Kreienbring, Katrin, et al.
Publicado: (2016)

Hemodynamic Consequences of Malignant Ascites in Epithelial Ovarian Cancer Surgery(∗): A Prospective Substudy of a Randomized Controlled Trial
por: Hunsicker, Oliver, et al.
Publicado: (2015)

Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer
por: Dědová, Tereza, et al.
Publicado: (2019)

Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report
por: Passler, Mona, et al.
Publicado: (2019)

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer
por: Woopen, Hannah, et al.
Publicado: (2014)

Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer
por: Kulbe, Hagen, et al.
Publicado: (2019)

Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer
por: Mungenast, Felicitas, et al.
Publicado: (2017)

Neutrophil Granulocytes in Ovarian Cancer - Induction of Epithelial-To-Mesenchymal-Transition and Tumor Cell Migration
por: Mayer, Christine, et al.
Publicado: (2016)

Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance
por: Lorusso, Domenica, et al.
Publicado: (2020)

Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death
por: Guo, Fang, et al.
Publicado: (2022)

Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer
por: Sun, PengMing, et al.
Publicado: (2018)

Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo
por: Teck, Anja Tatjana, et al.
Publicado: (2020)

Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A*02:01‑restricted T cell epitopes, which are presented and recognized in vivo
por: Teck, Anja Tatjana, et al.
Publicado: (2021)

Primary Treatment Results in Patients with Ovarian, Fallopian or Peritoneal Cancer—Results of a Clinical Cancer Registry Database Analysis in Germany
por: Armbrust, Robert, et al.
Publicado: (2022)

Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients
por: Gericke, Beate, et al.
Publicado: (2005)

Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination
por: Busse, Antonia, et al.
Publicado: (2010)

Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
por: Baum, Joanna, et al.
Publicado: (2023)

Interkulturelle Kompetenzen im Gesundheitswesen durch Fort- und Weiterbildungen fördern
por: Dimitrova, Desislava, et al.
Publicado: (2023)

HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer
por: Arsenic, Ruza, et al.
Publicado: (2015)

Checkpoint-inhibition in ovarian cancer: rising star or just a dream?
por: Pietzner, Klaus, et al.
Publicado: (2018)

Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis
por: Cherif, Soumia, et al.
Publicado: (2021)

CT Fluoroscopy-Guided Percutaneous Gastrostomy in the Palliative Management of Advanced and Relapsed Ovarian Cancer: The Charité Experiences and a Review of the Literature
por: Canaz, Emel, et al.
Publicado: (2023)

ECOG and BMI as preoperative risk factors for severe postoperative complications in ovarian cancer patients: results of a prospective study (RISC-GYN—trial)
por: Inci, Melisa Guelhan, et al.
Publicado: (2021)

Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HR-QoL) in Patients with Ovarian Cancer: What Is Different Compared to Healthy Women?
por: Inci, Melisa Guelhan, et al.
Publicado: (2021)

Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment
por: Busse, Antonia, et al.
Publicado: (2020)

Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populations
por: Ochsenreither, Sebastian, et al.
Publicado: (2008)

Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study
por: Runnebaum, Ingo B., et al.
Publicado: (2018)

Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patients
por: Ochsenreither, Sebastian, et al.
Publicado: (2010)

Long term efficacy of WT1 peptide vaccine in patients with WT1 overexpressing hematopoeitic and solid malignancies
por: Letsch, Anne, et al.
Publicado: (2013)

Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test)
por: Kischkel, Frank Christian, et al.
Publicado: (2017)

Immunoglobulin G Subclass-Specific Glycosylation Changes in Primary Epithelial Ovarian Cancer
por: Wieczorek, Marta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3vmss6gg40m3sbfb606jf0rv5j